| Literature DB >> 31455576 |
Jason Taam1, Qi Joy Yang2, K Sandy Pang2, Paul Karanicolas3, Stephen Choi4, Marcin Wasowicz5, Angela Jerath6.
Abstract
Tranexamic acid reduces blood loss and transfusion requirements with no significant thrombotic adverse effects. Postoperative seizures have been seen in cardiac surgical patients in association with patient (advanced age, underlying neurologic disease, chronic kidney disease); surgical (open cardiac procedures, long bypass times); and drug (high tranexamic acid dose) risk factors. Tranexamic acid dosing regimens should be decreased in patients with chronic kidney dysfunction secondary to reduced clearance and drug accumulation. Optimal dosing for cardiac surgical patients has been recommended. Additional research is required to determine dosing regimens in major noncardiac surgery and plasma concentration levels associated with inducing seizures.Entities:
Keywords: Tranexamic acid; antifibrinolytic; blood conservation; cardiac surgery; cardiopulmonary bypass; chronic kidney dysfunction; dose; fibrin; noncardiac surgery; pharmacokinetics; safety; seizures; transfusion; trial
Mesh:
Substances:
Year: 2019 PMID: 31455576 DOI: 10.1053/j.jvca.2019.06.042
Source DB: PubMed Journal: J Cardiothorac Vasc Anesth ISSN: 1053-0770 Impact factor: 2.628